Evidence map›Paper›PMID 30341287›Full record

ArticleNature communications2018

Neurokinin-3 receptor activation selectively prolongs atrial refractoriness by inhibition of a background K

Marieke W Veldkamp, Guillaume S C Geuzebroek, Antonius Baartscheer, Arie O Verkerk, Cees A Schumacher, Gedeon G Suarez, Wouter R Berger, Simona Casini, Shirley C M van Amersfoorth, Koen T Scholman and 8 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. The Antidepressant Paroxetine Reduces the Cardiac Sodium Current.International journal of molecular sciences · 2023
    Article
  4. Article
  5. Small conductance calcium activated KInternational journal of cardiology. Heart & vasculature · 2021
    Article
  6. Absence of Functional NaCardiovascular drugs and therapy · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 2 countries.

Marieke W VeldkampDepartment of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. m.w.veldkamp@amc.uva.nl.
Guillaume S C GeuzebroekDepartment of Cardiothoracic Surgery, RadboudUMC, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands.
Antonius BaartscheerDepartment of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Arie O VerkerkDepartment of Medical Biology, Academic Medical Center Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Cees A SchumacherDepartment of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Gedeon G SuarezBiomedical Sciences VU University Medical Center, De Boelelaan 1105, 1081 HV, Amsterdam, The Netherlands.
Wouter R BergerDepartment of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Simona CasiniDepartment of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Shirley C M van AmersfoorthDepartment of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Koen T ScholmanDepartment of Medical Biology, Academic Medical Center Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Antoine H G DriessenDepartment of Cardiothoracic Surgery, Heart Center, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Charly N W BeltermanDepartment of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Antoni C G van GinnekenDepartment of Medical Biology, Academic Medical Center Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Joris R de GrootDepartment of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Jacques M T de BakkerDepartment of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Carol Ann RemmeDepartment of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Bas J BoukensDepartment of Medical Biology, Academic Medical Center Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Ruben CoronelDepartment of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Academic Medical Center · NLAmsterdam UMC Location VUmc · NLElectrophysiology and Heart Modeling Institute · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cardiac autonomic nervous system (ANS) controls normal atrial electrical function. The cardiac ANS produces various neuropeptides, among which the neurokinins, whose actions on atrial electrophysiology are largely unknown. We here demonstrate that the neurokinin substance-P (Sub-P) activates a neurokinin-3 receptor (NK-3R) in rabbit, prolonging action potential (AP) duration through inhibition of a background potassium current. In contrast, ventricular AP duration was unaffected by NK-3R activation. NK-3R stimulation lengthened atrial repolarization in intact rabbit hearts and consequently suppressed arrhythmia duration and occurrence in a rabbit isolated heart model of atrial fibrillation (AF). In human atrial appendages, the phenomenon of NK-3R mediated lengthening of atrial repolarization was also observed. Our findings thus uncover a pathway to selectively modulate atrial AP duration by activation of a hitherto unidentified neurokinin-3 receptor in the membrane of atrial myocytes. NK-3R stimulation may therefore represent an anti-arrhythmic concept to suppress re-entry-based atrial tachyarrhythmias, including AF.

Indexed as

Action PotentialsAnimalsArrhythmias, CardiacAtrial FibrillationAtrial FunctionHeart AtriaHumansPotassium Channel BlockersPotassium ChannelsRabbitsReceptors, Neurokinin-3Potassium Channel BlockersPotassium ChannelsReceptors, Neurokinin-3

Identifiers

PMID30341287
PMCPMC6195571
OpenAlexW2897495776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.